3C
CCXI

361 Capital’s ChemoCentryx, Inc. CCXI Stock Holding History

361 Capital’s Portfolio CCXI Stock Details CCXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-197,562
Closed -$1.84M – 395
2019
Q2 		$1.84M Buy
197,562
+151,219
+326% +$1.75M 0.33% 161
2019
Q1 		$644K Buy
+46,343
New +$530K 0.11% 255

Other funds holding CCXI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

361 Capital's CCXI Position: Q3 2019 in Review

361 Capital sold out of ChemoCentryx, Inc. (CCXI) in Q3 2019, closing a stake of 197,562 shares — an estimated $1.84M sold.

361 Capital first reported a position in CCXI in Q1 2019 and held it in 2 quarters. The position peaked at $1.84M in Q2 2019. 100 funds tracked by Wall St. Rank hold CCXI as of Q3 2019.

  • 361 Capital reported no remaining ChemoCentryx, Inc. position as of Q3 2019 after selling out during the quarter.
  • 361 Capital sold 197,562 ChemoCentryx, Inc. shares in Q3 2019, an estimated $1.84M.
  • 361 Capital first reported a position in ChemoCentryx, Inc. in Q1 2019 and held it in 2 quarters.
  • 361 Capital's ChemoCentryx, Inc. position peaked at $1.84M in Q2 2019.
  • 100 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q3 2019.

Based on 361 Capital's 13F filing for Q3 2019, filed 14 Nov 2019.